Cara Therapeutics | CARA - Pre Tax Profit


Cara Therapeutics reported $-6.8M in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 46.47M 42.49M Jun/2026
Alterity Therapeutics Limited AUD -6.26M 1.52M Dec/2025
Cara Therapeutics USD -6.8M 1.9M Mar/2026
Cassava Sciences USD -10.81M 33.41M Sep/2025
Chugai Pharma JPY 169.02B 8.83B Jun/2026
Cipla INR 10.82B 3.33B Jun/2026
Clal Biotechnology ILS 86.82M 17.9M Dec/2022
Compugen USD -7.66M 64.51M Mar/2026
CSL USD 2.61B 1.21B Dec/2025
Grifols EUR 257.85M 190.87M Dec/2024
Halozyme Therapeutics USD 180.33M 281.18M Mar/2026
J&J USD 8.66B 839M Jun/2026
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
Pacira USD 5M 4.43M Mar/2026
Pfizer USD -653M 5.84B Jun/2026
RedHill Biopharma USD -1.54M 12M Jun/2024
Supernus Pharmaceuticals USD -57.65M 51.7M Jun/2026
Vanda Pharmaceuticals USD -22.92M 16.68M Dec/2024